Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
Identifieur interne : 003B79 ( Main/Exploration ); précédent : 003B78; suivant : 003B80Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
Auteurs : Xavier Mariette [France] ; Jacques-Eric Gottenberg [France] ; Philippe Ravaud [France] ; Bernard Combe [France]Source :
- Rheumatology : (Oxford. Print) [ 1462-0324 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objectives. Clinical registries have shown their effectiveness in capturing the long-term benefit of drugs in routine care. In France, two types of registry have been established to analyse the safety and efficacy of biological agents. Methods. The Research Axed on Tolerance of Biotherapies (RATIO) registry was designed to prospectively collect all cases of lymphoma and opportunistic infections occurring in patients receiving anti-TNF blockers for any indication. We also examined the results from nationwide prospective cohorts in order to investigate the safety and efficacy of rituximab (RTX), abatacept (ABA) and tocilizumab in RA and other autoimmune diseases. Results. Analysis of the RATIO registry demonstrated an increased risk of Legionella pneumophila infection in patients receiving anti-TNF therapy, a higher risk of tuberculosis [odds ratio (OR) (95% CI): 13.3 (2.6, 69.0) and 17.1 (3.6, 80.6) for infliximab and adalimumab vs etanercept, respectively], opportunistic infections and incidence of lymphoma, with mAb than with soluble-receptor anti-TNF. The characteristics of RA patients in RTX and ABA registries showed that some patients did not receive previous TNF blockers [20% in autoimmunity and RTX (AIR) and 13% in Orencia and RA (ORA)] and one-third of them were treated without concomitant DMARDs. Patients receiving RTX showed an increased proportion of severe infections (5.0/100 patient-years). Lung and cardiac comorbidities, extra-articular involvement and low immunoglobulin G before RTX were predictive factors of severe infections. In addition, the AIR registry suggested the effectiveness of RTX in patients with SLE. Conclusion. The establishment of biological registries in rheumatic diseases, in France, with their different methods, has already provided additional data to controlled trials, mainly on the risk of severe infections and lymphoma.
Affiliations:
- France
- Alsace (région administrative), Grand Est, Languedoc-Roussillon, Occitanie (région administrative), Île-de-France
- Montpellier, Paris, Strasbourg
- Université de Strasbourg
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000167
- to stream PascalFrancis, to step Curation: 000097
- to stream PascalFrancis, to step Checkpoint: 000146
- to stream Main, to step Merge: 003C20
- to stream Main, to step Curation: 003B79
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries</title><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rheumatology Department, Hôpital Bicetre, AP-HP; University Paris-Sud 11 V; INSERM U1012</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gottenberg, Jacques Eric" sort="Gottenberg, Jacques Eric" uniqKey="Gottenberg J" first="Jacques-Eric" last="Gottenberg">Jacques-Eric Gottenberg</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Rheumatology Department, EA 4438, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Université de Strasbourg</wicri:noRegion><placeName><settlement type="city">Strasbourg</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Ravaud, Philippe" sort="Ravaud, Philippe" uniqKey="Ravaud P" first="Philippe" last="Ravaud">Philippe Ravaud</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Epidemiology Clinic Department, Hôpital Hôtel Dieu, AP-HP; University Paris V; INSERM U738</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Rheumatology Department, Hôpital Lapeyronie, Montpellier I University, UMR 5535</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0157515</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0157515 INIST</idno><idno type="RBID">Pascal:11-0157515</idno><idno type="wicri:Area/PascalFrancis/Corpus">000167</idno><idno type="wicri:Area/PascalFrancis/Curation">000097</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000146</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000146</idno><idno type="wicri:doubleKey">1462-0324:2011:Mariette X:registries:in:rheumatoid</idno><idno type="wicri:Area/Main/Merge">003C20</idno><idno type="wicri:Area/Main/Curation">003B79</idno><idno type="wicri:Area/Main/Exploration">003B79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries</title><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Rheumatology Department, Hôpital Bicetre, AP-HP; University Paris-Sud 11 V; INSERM U1012</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gottenberg, Jacques Eric" sort="Gottenberg, Jacques Eric" uniqKey="Gottenberg J" first="Jacques-Eric" last="Gottenberg">Jacques-Eric Gottenberg</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Rheumatology Department, EA 4438, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Université de Strasbourg</wicri:noRegion><placeName><settlement type="city">Strasbourg</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Ravaud, Philippe" sort="Ravaud, Philippe" uniqKey="Ravaud P" first="Philippe" last="Ravaud">Philippe Ravaud</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Epidemiology Clinic Department, Hôpital Hôtel Dieu, AP-HP; University Paris V; INSERM U738</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Rheumatology Department, Hôpital Lapeyronie, Montpellier I University, UMR 5535</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Rheumatology : (Oxford. Print)</title><title level="j" type="abbreviated">Rheumatol. : (Oxf. Print)</title><idno type="ISSN">1462-0324</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Rheumatology : (Oxford. Print)</title><title level="j" type="abbreviated">Rheumatol. : (Oxf. Print)</title><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept</term><term>Antineoplastic agent</term><term>Autoimmune disease</term><term>Chronic</term><term>French</term><term>Immunomodulator</term><term>Immunosuppressive agent</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Rituximab</term><term>Systemic lupus erythematosus</term><term>Tumor necrosis factor</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Lupus érythémateux disséminé</term><term>Rituximab</term><term>Abatacept</term><term>Maladie autoimmune</term><term>Français</term><term>Facteur nécrose tumorale</term><term>Rhumatologie</term><term>Chronique</term><term>Anticancéreux</term><term>Immunomodulateur</term><term>Immunodépresseur</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives. Clinical registries have shown their effectiveness in capturing the long-term benefit of drugs in routine care. In France, two types of registry have been established to analyse the safety and efficacy of biological agents. Methods. The Research Axed on Tolerance of Biotherapies (RATIO) registry was designed to prospectively collect all cases of lymphoma and opportunistic infections occurring in patients receiving anti-TNF blockers for any indication. We also examined the results from nationwide prospective cohorts in order to investigate the safety and efficacy of rituximab (RTX), abatacept (ABA) and tocilizumab in RA and other autoimmune diseases. Results. Analysis of the RATIO registry demonstrated an increased risk of Legionella pneumophila infection in patients receiving anti-TNF therapy, a higher risk of tuberculosis [odds ratio (OR) (95% CI): 13.3 (2.6, 69.0) and 17.1 (3.6, 80.6) for infliximab and adalimumab vs etanercept, respectively], opportunistic infections and incidence of lymphoma, with mAb than with soluble-receptor anti-TNF. The characteristics of RA patients in RTX and ABA registries showed that some patients did not receive previous TNF blockers [20% in autoimmunity and RTX (AIR) and 13% in Orencia and RA (ORA)] and one-third of them were treated without concomitant DMARDs. Patients receiving RTX showed an increased proportion of severe infections (5.0/100 patient-years). Lung and cardiac comorbidities, extra-articular involvement and low immunoglobulin G before RTX were predictive factors of severe infections. In addition, the AIR registry suggested the effectiveness of RTX in patients with SLE. Conclusion. The establishment of biological registries in rheumatic diseases, in France, with their different methods, has already provided additional data to controlled trials, mainly on the risk of severe infections and lymphoma.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Alsace (région administrative)</li><li>Grand Est</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>Île-de-France</li></region><settlement><li>Montpellier</li><li>Paris</li><li>Strasbourg</li></settlement><orgName><li>Université de Strasbourg</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name></region><name sortKey="Combe, Bernard" sort="Combe, Bernard" uniqKey="Combe B" first="Bernard" last="Combe">Bernard Combe</name><name sortKey="Gottenberg, Jacques Eric" sort="Gottenberg, Jacques Eric" uniqKey="Gottenberg J" first="Jacques-Eric" last="Gottenberg">Jacques-Eric Gottenberg</name><name sortKey="Ravaud, Philippe" sort="Ravaud, Philippe" uniqKey="Ravaud P" first="Philippe" last="Ravaud">Philippe Ravaud</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0157515
|texte= Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
}}
| This area was generated with Dilib version V0.6.34. |  |